Defining Novel Targets and Validating Endpoints to Accelerate First-in-Class Therapeutics for Dry AMD & Geographic Atrophy
Thank you to our speakers, sponsors and delegates who joined us in 2025 for the summit!
If you are interested in the 2026 event please get in touch at info@hansonwade.com
Companies Attended in 2025:
The 6th Dry AMD and Geographic Atrophy Therapeutics Summit
Transformative Therapies for Dry, Intermediate & Late-Stage AMD
With late-phase trials advancing, novel mechanisms emerging, and global regulatory expectations evolving, the dry AMD and GA field is accelerating exponentially. Returning digitally for its sixth year, this summit was the only industry-led forum focused exclusively on the therapeutic development for dry AMD and GA.
Attendees heard from 19+ experts across biotech, investment, and consulting, including leaders from Apellis, Ocugen, Clearside Biomedical, Annexon, and VisgenX, as well as FDA-experienced advisors and global investors - as they showcased how to navigate regulatory complexity, de-risk development decisions, and accelerate novel dry AMD and Geographic atrophy therapies toward clinical and commercial success.
Join us at this exclusive forum in 2026 to stay ahead of the field with real-time updates on retinal clinical strategy, evolving regulatory expectations, precision ocular delivery innovation, and investment trends shaping the future of dry AMD and geographic atrophy therapeutics.
Download the 2025 Event Guide for More Information On:
- 19+ Expert Speaker Faculty
- Interactive Workshops
- Full access to the 3-day agenda and scientific content breakdown
- and more!
2025 World-Class Speaker Faculty Included:
Previously Attended Companies:
Testimonials:
“I’m thrilled to join this panel and contribute to the dialogue around advancing therapies for dry AMD and geographic atrophy. With a background in investing across life sciences and healthcare IT, and deep relationships in venture capital and private equity, I understand what it takes to move promising science into the clinic. This is a critical moment for retinal innovation, and I’m excited to help spotlight the strategies and partnerships that can accelerate progress for patients.”
Jeanne Hecht, CEO & Chairwoman of the Board, Lexitas Pharma Services
“Excellent knowledgeable speakers, interactive, wide range of industry from start-ups to strategies, discussion of challenges not just successes including regulatory perspectives. The basic scientists and clinicians added great flavor”
Associate Director, Ophthalmology, Dompe International
2025 Partners:
Other Events in the Series:
